Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder ...

Sublocade offers important benefits not currently provided by the sublingual form of buprenorphine. Medication is steadily released into the blood stream, which helps patients to be compliant with ...

A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with ...

Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by Indivior, Inc. has been granted Priority ...

SUBLOCADE should not be administered to patients who have been shown to be hypersensitive to buprenorphine or any component of Indivior's proprietary buprenorphine gel depot delivery system.

Buprenorphine is a generic drug prescribed to manage pain and opioid use disorder. It’s available as the brand-name drugs Sublocade, Butrans, and others. The cost of buprenorphine, with and ...

SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use [package insert]. North Chesterfield, VA: Indivior PLC; 2025. Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM.